Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.

Slides:

Advertisements

Similar presentations

Serotonin & Anti-serotonin drugs At the end of this session students should be able to: Describe serotonin (5HT) receptors including serotonin & antiserotonin.

Advertisements

Acute treatment of migraine Dr Mark Weatherall London Headache Centre 2010.

The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment.

Symptom Control and Enhancing Functioning in Schizophrenia

MOnoclonal antibodies and potential applications in migraine

Incorporating New Therapies in IBS-C

CGRP THERAPEUTIC MONOCLONAL ANTIBODIES

IL-12 and IL-23.

Olivia Moderator: Dr. Yugrakh EBN February 2018

Update on the Diagnosis and Management of CTEPH in Latin America

Bipolar Disorder: Latest Clinical Update

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

The "Metabolically Healthy Obese"

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

This talk will follow the topical structure suggested by the ABP:

Current Controversies in Multiple Sclerosis Management

Migraine Prevention Therapy: Avoiding Overuse of Medications

Introduction Antiplatelet Agents ADP Receptor Antagonists.

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Can Primary Care Physicians Take the Lead in Combating Obesity?

Case Challenges in Chronic Migraine

Please consider these data to be preliminary until they have been published in peer-reviewed journals.

Surveying the Safety of NOACs in the Real World

Insight Into the Latest Findings in Migraine

The Vicious Cycle of Chronic Migraine How Can the Physician Help?

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Metabolically Healthy Patients With Obesity

Updates in Migraine From a 2018 American Headache Meeting

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

An Update on PCSK9 Inhibitors

Diagnostic and Management Challenges in Patients With Chronic Migraine

Treating mRCC After Initial Antiangiogenic Therapy:

Efficacy and Safety of Edoxaban in Patients With AF and HF

TAVR and the Risk of Thrombosis

Results w the CI.

Demographics of IPF in the USa-d

Demystifying the Science of Monoclonal Antibodies in Migraine

Poor Response to Initial Therapy for Migraine

CGRP Antibodies in Migraine

Current and Future Perspectives on Migraine Prevention Therapy

Advancing the Treatment of IBD With Biologics

Using Heart Rate as a Biomarker in Clinical Practice.

Breaking New Ground With Migraine Prevention Therapies

Updates in Heart Failure:

Updates in Cardiovascular Medicine

Oral Prostanoids and PAH

Getting to Grips With the Science of CGRP and Migraine

When Is Intrathecal Drug Delivery Appropriate?

(p-value between groups = 0.59)

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

Clinical Challenges and Updates in Managing Seizure Clusters

When Is Intrathecal Drug Delivery Appropriate?

The Biologic Basis of Migraine

PAH Pathways: What Do the Data Tell Us?”

Migraine Therapeutics in Development

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Diagnostic Criteria Migraine Without Aura

Identifying TRK Fusions in Head and Neck Cancer

Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.

Key Data on Improving Outcomes in HF Patients

A New Era in Migraine Prevention

Risk Factors for Migraine Chronification

Rethinking Risk Stratification for Nonischemic HF:

The Power of As-Treated Analyses

Late-Breaking Data on LDL-C Reduction

Translating Data From Trial to Practice

Presentation transcript:

Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine

Introduction Migraine

Introduction Migraine Treatments

What Is CGRP?

Function of CGRP

CGRP Pathophysiology Effect of Infusion of hα-CGRP

Small Molecules (Gepants) vs mAbs

Initial CGRP Antagonists (Gepants)

Other CGRP Antagonists (Gepants)

Ubrogepant Trial Design and Results

Clinical Implications of Small Molecule CGRP Antagonists Gepants

Gepants vs Triptans

mAbs

Immunogenicity Potential for mAbs

CGRP mAbs

ALD403 Study Design

ALD403 Study Results

Galcanezumab Study Design

Galcanezumab Study Results

TEV-48125 Study Design

TEV-48125 Study Results

TEV-48125 Study Design

TEV-48125 Post Hoc Analysis in Chronic Migraine

Erenumab Study Design and Results in Episodic Migraine

Erenumab Study Design in Chronic Migraine

Erenumab Study Results in Chronic Migraine

Summary mAbs

Breakthrough Headache

Triptan Targets

Potential but Unknown Cardiovascular and Cerebrovascular Risks With CGRP Blockade

GCRP Receptor Complex

Conclusions

Abbreviations